CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02345265
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:18.365885+00:00
Published At: 2023-03-28T00:00:00+00:00
Record Updated At: 2026-03-05
Results Posted At: 2023-03-28
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Fallopian Tube Carcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Ovarian Carcinoma", "Ovarian High Grade Endometrioid Adenocarcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Primary Peritoneal Carcinoma", "Primary Peritoneal Endometrioid Adenocarcinoma", "Primary Peritoneal Serous Adenocarcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-03-05"
protocolSection.identificationModule.nctId: "NCT02345265"
protocolSection.identificationModule.officialTitle: "A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2023-03-28"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.